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Edited by Gianni CesareniAbstract Estrogen receptor-alpha (ER-a) is a nuclear tran-
scriptional factor that is part of the nuclear receptor superfamily.
In this study, we isolated and identiﬁed a new LXXLL-
containing protein that interacts with the ER-a via a yeast
two-hybrid assay. We have termed this protein estrogen receptor
repressor-10 (ERR-10). The ERR-10 cDNA is predicted to
encode a polypeptide of 94 amino acids, with a molecular mass of
about 10 kDa. Although the ERR-10 mRNA transcript is
expressed in a wide range of normal human tissues, higher
expression levels are found in endocrinal tissues relative to other
tissues. We have demonstrated, through immunoprecipitation,
Western blot and GST pull-down assays, that ERR-10 associ-
ates with ER-a. Moreover, ERR-10 decreased 17b-estrodial-
induced activation of ER-a transcriptional activity in transient
transfection assays of mammalian cells. The ERR-10 N-
terminus, which resembles two LXXLL motifs, is essential for
ER-a binding and repression activity. Estrogen modulation of
estrogen-responsive gene expression was markedly blocked by
ERR-10. These results suggest that ERR-10 is a novel mediator
in ER transcriptional activation.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Estrogen inﬂuences gene expression and aﬀects cellular
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Abbreviations: ER, estrogen receptor; NR, nuclear receptor; AF,
activation function; DBD, DNA-binding domain; LBD, ligand-bind-
ing domain; ERR-10, estrogen receptor repressor-10; FCS, fetal calf
serum; ERE, estrogen response element; wt, wild type; mut, mutant;
GST, glutathione S-transferase; PCR, polymerase chain reaction; bp,
base pair(s); IVT, in vitro transcribed and translated; efp, estrogen-
responsive ﬁnger protein; S.E., standard error
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doi:10.1016/j.febslet.2004.07.094speciﬁc estrogen receptors (ER, a and b). ERs belong to the
nuclear receptor (NR) superfamily. NRs share common
structural and functional features, including acting as tran-
scriptional factors when bound by their appropriate ligands
[1–5]. The classical ER (now called ER-a or ER) consists of
595 amino acids and exhibits a modular structure comprised of
several domains labeled A–F, with three functional domains
[6,7]: an N-terminal region, containing a constitutive activa-
tion function (AF-1); a central, highly conserved DNA-bind-
ing domain (DBD); and a C-terminal ligand-binding domain
(LBD), containing a dimerization and a ligand-transactivation
function (AF-2). The AF-1 domain is hormone-independent,
whereas the AF-2 domain is hormone-dependent [8–10]. Both
domains are required for maximal ER transcriptional activity;
however, each is capable of functioning independently [8–10].
Like other activation domains, the AFs of ER are important
targets for basal transcriptional factors and cellular proteins
that function as co-regulators. In the absence of a ligand, the
ER exists in a transcriptionally inactive state, associated with
heat-shock proteins and other cellular chaperones. Upon ac-
tivation by hormone binding, the ER-a receptor undergoes a
conformational change of the LBD and dissociates from the
heat-shock proteins, allowing the receptor to dimerize and
interact speciﬁcally with a cis-acting DNA sequence called the
estrogen response element (ERE) within regulatory regions of
target genes to activate or repress transcription [3,11,12], and
references therein.
Many of the tissue-speciﬁc eﬀects of ER are dependent on
the cellular pool of co-regulators and other nuclear proteins
that inﬂuence ER transcriptional activities [13–16], and ref-
erences therein. These proteins function as signaling inter-
mediates between ER and the general transcriptional
machinery to increase ER transcriptional activity (as co-acti-
vators), reduce its transcriptional activity (as co-repressors),
or act as protein adaptors for other diverse transcriptional
signaling proteins.
Functional and structural studies have elucidated that the
precise mechanisms of the interaction between several dif-
ferent co-regulators and the ligand-inducible activation do-
main of ER take place through short leucine-rich sequences
known as LXXLL motifs, or NR-Boxes (Table 1) [17–33].
For example, the LXXLL motifs present in co-activators
PERC and in co-repressors DAX-1 are regarded as essentialation of European Biochemical Societies.
Table 1
Amino acid sequence of the NR-interaction box (NR-Box, LXXLL) in diﬀerent ER co-activators and co-repressors
Gene LXXLL motif (aa) Role in ER Activity Ref.
CIA SLINLLAD (386–393) Activator [17]
DAX-1 ILYSLLTS (145–152) Repressor [18]
DRIP ALRHLLFL (470–477) Activator [19]
TLKSLLRP (559–566)
PLFRLLTK (720–727)
KLFDLLYP (397–404)
PLKGLLPY (251–258)
ILHTLLEM (599–596)
SLETLLDH (783–790)
GRIP1 KLLQLLTT (640–647) Activator [20]
ILHRLLQD (689–696)
LLRYLLDK (744–751)
QLGRLLPN (877–884)
LZIP DLLALLEE (12–19) Activator [21]
DLLSLLSP (52–59)
p300 KLSELLRS (80–87) Activator [22]
QLVLLLHA (341–348)
ALQNLLRT (2050–1057)
P/CAF YLFGLLRK (189–196) Activator [23]
PELP1 CLLSLLYG (28–35) Activator [24]
VLRDLLRY (72–79)
HLPGLLTS (94–101)
LLTSLLGL (98–105)
ELHSLLAS (181–188)
SLHTLLGA (188–195)
PLRLLLLP (281–289)
LLTHLLSD (376–383)
ELYCLLLA (496–503)
LLALLLAP (501–508)
PERC LLQKLLLA (155–162) Activator [25]
ILRELLAQ (342–349)
PGC-1 LLKKLLLA (143–147) Activator [26]
PRIP LLVNLLQS (891–898) Activator [27]
SLSQLLDN (1495–1502)
RAP250 LLVNLLQS (886–893) Activator [28]
SLSQLLDN (1490–1497)
RIP140 YLEGLLMH (20–27) Activator [29]
LLASLLQS (132–139)
HLKTLLKK (184–191)
QLALLLSS (265–272)
LLLHLLKS (379–386)
LLLLLLGH (499–506)
VLQLLLGN (712–719)
LLSRLLRQ (818–825)
VLKQLLLS (935–972)
R-MGMT VLWKLLKV (95–105) Repressor [30]
SHP-1 ILYALLTS (19–26) Repressor [18]
SRC-1 KLVQLLTT (252–260) Activator [31,32]
ILHRLLQE (309–318)
LLRYLLDK (368–375)
QLDELLCP (532–539)
LLQQLLTE (1054–1061)
TRAP220 ILTSLLQI (603–610) Activator [33]
MLMNLLKD (644–651)
TRBP LLVNLLQS (886–893) Activator [19]
LLSQLLDN (1490–1497)
CIA, co-activator independent of AF-2 function; DAX-1, dosage-sensitive sex reversal, adrenal hypoplasia congenital critical region on the X
chromosome, gene 1; DRIP, vitamin D receptor interacting protein; GRIP1, glucocorticoid receptor interacting protein 1; PELP1, proline-, glutamic
acid-, and leucine-rich protein-1; LZIP, leucine zipper protein; PERC, PGC-1 related estrogen receptor co-activator; P/CAF, p300/CBP-associated
factor; PGC-1, peroxisome proliferator-activated receptor-c co-activator-1; PRIP, peroxisome proliferator-activated receptor-interacting protein
(also referred to as MNAR, or modulator of nongenomic activity of ER); RAP250, Nuclear receptor-activating protein, 250 kDa; RIP140, receptor-
interacting protein 140 (also named Nrip1, nuclear-receptor-interacting protein 1); R-MGMT, O(6)-methylguanine-DNA methyltransferase; SHP-1,
Src homology phosphatase-1; SRC-1, steroid-receptor co-activator 1; TRAP220, thyroid hormone receptor-associated protein, 220 kDa; TRBP,
TAR RNA- binding protein.
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identify and characterize a new protein, named estrogen
receptor repressor-10 (ERR-10), which associates with ER-a
and attenuates ER-a transcriptional activity via two LXXLL
motifs.2. Materials and methods
2.1. Cell culture
All cell lines were purchased from the American Type Culture
Collection (ATCC) and maintained as monolayer cultures in
192 Q. Meng et al. / FEBS Letters 576 (2004) 190–200RPMI-1640 or Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% fetal calf serum (FCS), 2 mg/l glutamine, 0.1 mg/l strep-
tomycin, and 1000 U/l penicillin G (Gibco), at 37 C in a humidiﬁed
atmosphere of 5% CO2 in air. Phenol red-free medium and dextran-
coated charcoal-treated FCS were used in experiments to assess the
impact of E2.
2.2. Expression plasmids and reporters
All vectors were generated using standard cloning procedures and
veriﬁed by restriction enzyme analysis and DNA sequencing. The
wild-type expression vector pCMV-ER-a (ER-a) was used to express
ER-a. The ERE2-TK-LUC reporter, composed of the vitellogenin A2
ERE controlling a minimal thymidine kinase promoter (TK81) and
luciferase in a pGL2 plasmid, has been described in our previous
studies [34–37]. The wild-type ERR-10 (wt-ERR-10) expression
plasmid was created by cloning the full-length ERR-10 cDNA into a
mammalian pCMV-Tag2B expression vector (Stratagene), which
allows for the expression of proteins with an N-terminal FLAG
sequence. LXXLL-mutated ERR-10 (ERR-10-Box1mut, ERR-10-
Box2mut, and ERR-10-Box1/2mut) expression plasmids were created
by replacing leucines in the critical +4 and +5 positions of the
LXXLL motifs with alanines (e.g., LXXLL!LXXAA) in wt-ERR-
10 cDNA. Gal4-LUC, gal4-ER-a, glutathione S-transferase (GST)-
ER-a, and GST-ER-a mutant (mut) constructs have been described
in previous studies [34–37]. The CAT reporter vectors B1ERE-CAT,
pS2ERE-CAT, and OTERE-CAT, which contain the B1ERE se-
quence CAGTCACTGGTACCC, pS2ERE sequence AG-
GTCACGGTGGCCA, OTERE sequence CGGTCACGGTCACCT,
and Cyclin D1 promoter vector (CD1-LUC), were kindly provided
by Richard G Pestell (Lombardi Comprehensive Cancer Center,
Georgetown University, Washington, DC).
2.3. ERR-10 antibody
Bacterially expressed GST-ERR-10 (amino acids 15–85) was puriﬁed
by aﬃnity chomatography on glutathione–Sepharose 4B (Amersham
Pharmacia Biotech) and eluted in a buﬀer containing 10 mM reduced
glutathione in 50 mM Tris–HCl (pH 8.0). Polyclonal sera were raised
against puriﬁed GST-ERR-10 in rabbits and aﬃnity-puriﬁed.
2.4. Yeast two-hybrid screen
To isolate cDNA-encoding proteins that interact with ER-a, a yeast
two-hybrid screening was carried out using the LBD and AF-2 do-
main of ER-a linked to the rat DBD of gal4 (gal4-ER-LBD/AF-2) as a
bait. The protocol for the Benton and Davis method [38] for cDNA
library screening was followed. After several rounds of screening with
a human brain cDNA library (Clontech) in yeast strain CG1945, a
pure positive 1910-base pair (bp) clone was identiﬁed and sequenced.
Both strands of the isolated cDNA clones were sequenced by dide-
oxynucleotide-chain termination methods, using a primer walking
strategy.
2.5. Northern blot assay
The ﬁlter forNorthern hybridization (Clontech) was hybridized to the
446-bp ERR-10 cDNA probe, which had been puriﬁed from agarose gel
using the QIAEX II gel extraction kit (Qiagen) and labeled with [a-
32P]dCTP (Amersham) by the random-prime method (Rediprime,
AmershamPharmaciaBiotech).TheClontechMultipleTissueNorthern
Blots contained 2 lg of oligo(dT)-puriﬁed mRNA from various normal
human tissues. Hybridization, washing, and X-ray ﬁlm exposure were
performed according to the manufacturer’s recommended protocol
(Clontech), as described in previous studies [34]. After stripping, the
same ﬁlter was hybridized to the b-actin probe as a control.
2.6. GST pull-down assay
GST pull-down assays were performed as described in previous
studies [35–37]. GST fusion proteins were ampliﬁed from Escherichia
coli strain BL21 grown in Luria–Bertani medium at 37 C to
mid-log phase and induced by 0.1 mM isopropyl-b-D-thiogalacto-
pyranoside for another 4 h at 30 C. Bacteria were harvested by
centrifugation and lysed by sonication in phosphate-buﬀered saline.
The lysates were spun at 10 000 g for 30 min at 4 C and the
supernatant was mixed with 50 ll of glutathione–agarose beads
(Gibco) for 2 h at 4 C. Beads were collected by centrifugation and
washed thee times in ice-cold phosphate-buﬀered saline. GST fusion
proteins were incubated in a binding buﬀer (10 mM NaCl, 1 mMEDTA, 20 mM Tris (pH 8.0), 0.2% Nonidet P-40, 1 mM dithio-
threitol, and 3% bovine serum albumin) with complete protease
inhibitors (Roche Molecular Biochemicals). Beads with the pure
GST fusion proteins were stored at 4 C. Aliquots of the beads were
boiled in 2 SDS loading buﬀer, separated by electrophoresis
though a 4–20% polyacrylamide gel, and blotted with an anti-GST
antibody (Santa Cruz) to analyze for bound proteins. Binding assays
were carried out in 0.5 ml of the reaction buﬀer containing GST
fusion protein (30 lg) with 30 ll of IVT [35S]methionine-labeled
protein (Promega). After overnight incubation, the beads were col-
lected by centrifugation, washed ﬁve times in the binding buﬀer, and
boiled in 2 SDS loading buﬀer. Bound proteins were separated by
electrophoresis though a pre-made 4–20% polyacrylamide gel. After
electrophoresis, the gel was ﬁxed for 30 min in ﬁxative solution
containing 30% methanol and 10% acetic acid, completely washed in
water for 30 min, incubated in 1 M sodium salicylate for 20 min,
dried, and exposed to ﬁlm at )80 C overnight.2.7. Immunoprecipitations (IP) and Western blotting (WB)
The in vivo association of ERR-10 and ER-a was achieved by IP–
WB, as described in previous studies [35–37]. IP with human 293T
cells was performed using cells cultured in 6-well plates 24 h prior to
transfection. The cells were transfected with a mammalian
pCMV-Tag2B-ERR-10 expression vector by lipofectAMINE 2000
(Invitrogen) with 20 lg of total DNA. Cells were harvested 48 h
post-transfection, then lysed in 1 ml of Nonidet P-40 lysis buﬀer
(1% Nonidet P-40, 150 mM NaCl, 5 mM EDTA, and protease
inhibitors). Cell lysates were clariﬁed by centrifugation at 18 000 g
for 15 min. ER-a IP from MCF-7 cells was performed using 2 lg of
aﬃnity-puriﬁed anti-ER-a polyclonal antibody (H222, H226, or a
combination of H222 and H226, Santa Cruz). 2 lg of normal mouse
IgG antibody was used as a negative IP control. ERR-10 was im-
munoprecipitated with 2 lg of anti-FLAG antibody (mouse
monoclonal, M2, Sigma) overnight at 4 C with 30 ll of a 50%
slurry of protein G–agarose (Roche Molecular Biochemicals). Im-
mune complexes were collected by low-speed centrifugation, washed
three times in 1% Nonidet P-40 lysis buﬀer, and boiled in 2 SDS
loading buﬀer. Denatured proteins were separated by SDS–poly-
acrylamide gel electrophoresis. Proteins were transferred to Immo-
bilon (Millipore Corp.), which was blocked in 5% non-fat milk, 150
mM NaCl, 10 mM Tris (pH 8.0), and 0.05% Tween. Immunoblots
were performed with anti-ERR-10 antisera or with an anti-ER-a
polyclonal antibody at 1 lg/ml (H-184, Santa Cruz Biotechnology,
CA) and developed by enhanced chemiluminescence (Amersham
Pharmacia Biotech). For WB assays of estrogen response genes
mediated by ERR-10, a polyclonal anti-estrogen-responsive ﬁnger
protein (efp) antibody (C-20), polyclonal anti-cathepsin D (C-20)
and monoclonal anti-cyclin D1 (HD-11) were purchased from Santa
Cruz Biotechnology, CA.2.8. Analysis of transcriptional activity
Transcriptional activity was assessed as described in previous
studies [34–37]. One day prior to transfection, cells were seeded at a
density of 4 103 cells/well in 24-well tissue culture dishes. Cells
were then transfected with LipofectAMINE 2000 (Invitrogen) ac-
cording to the manufacturer’s recommendations. Transfections were
performed with a constant mixture of 2 lg of the indicated DNA
(see ﬁgure legend). 250 ng cytomegalovirus (CMV)b-gal (CLON-
TECH Laboratories) for each transfection was used to normalize
each sample for transfection eﬃciency. The masses of the plasmids
are indicated in the ﬁgure legends. The transfected cells were then
subject to 17b-estrodial (E2) treatments (10 nM ﬁnal concentration;
Sigma) for 24 h prior to lysis. For luciferase activity, 40 ll of cell
lysate was assayed for luciferase activity, in accordance with the
manufacturer’s recommendations (Dual Luciferase, Promega). For
the determination of CAT activity, cell lysates were mixed with
acetyl CoA and [14C]chloramphenicol and post-incubated for 1 h at
37 C. Acetylated chloramphenicol and non-acetylated chloram-
phenicol were separated on Sil G TLC plates and ﬁnally quantitated
on a Molecular Dynamics Phosphorimager with ImageQuant soft-
ware (Molecular Dynamics). Student’s t tests were used to determine
whether statistical diﬀerences between ethanol and E2-treated groups
existed.
Table 2
Primers used for RT-PCR
Gene Primer pairs
ERR-10 50-CCC CAG AGT GAT GGC AGA CAA-30 (forward)
50-TTT GGG GAC TTG AGA TGT TTT G-30 (backward)
Efp 50-GTG CGG CCA CAA CTT CTG CG-30 (forward)
50-CTT TCA CGG CGG CCT CCT T-30 (backward)
E2IG4 50-CCT GAC TCG GGT GGA TTG TAG-30 (forward)
50-GAG AAG GCA GTG GGT GAG ATG C-30 (backward)
Cathepsin-D 50-GGG GCT CTG TGG AGG ACC TGA T-30 (forward)
50-AGA GGC TGA CGA CGC TGA CTG G-30 (backward)
Cyclin D1 50-GCT GCT CCT GGT GAA CAA GC-30 (forward)
50-TTC AAT GAA ATC GTG CGG G-30 (backward)
b-Actin 50-GTC AAC GGA TTT GGT CTG TAT T-30 (forward)
50-AGT CTT CTG GGT GGC AGT GAT-30 (backward)
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RT-PCR was carried out as described in previous studies [35–37].
cDNA was synthesized from 2 lg of total RNA in a 30-ll reaction
mixture containing 5 reverse transcriptase reaction buﬀer (Life Tech-
nologies, Inc., Gaithersburg, MD), 200 lM dNTP, 100 lM solution of
primers, 50 units of RNasin (Promega, Madison, WI), 10 mM dithio-
threitol, and 100 units of reverse transcriptase (Life Technologies, Inc.).
The mixture was incubated at 37 C for 60 min, heated to 95 C for 10
min, and then chilled on ice. PCR was carried out in a 50-ll volume
containing 10–20 ng of cDNA, chelating buﬀer (Perkin–Elmer Cetus,
Norwalk, CT), 20 lMdNTPmixture, 1.5 units of TaqDNApolymerase
(Perkin–ElmerCetus), and 0.5 lMof each primer (shown in Table 2). To
ensure that theRNAwasof suﬃcient purity to undergoRT-PCR, aPCR
assayusingprimers speciﬁc for theb-actin cDNAwas also performed for
each sample. The PCR products were electrophoresed on a 5% non-
denaturing polyacrylamide gel. The gel was then dried and exposed to an
imaging plate, and the radioactivity was determined using Bioimage
Analyzer (Bas1000; Fuji, Kanagawa, Japan).
2.10. Statistical analysis
The statistical analysis was performed using the two-tail Student’s t
test.3. Results and discussion
3.1. A new ER-interacting protein identiﬁed via yeast
two-hybrid screen
In an eﬀort to identify ER partner proteins, we cloned the
AF-2 domain of ER-a into the DBD of gal4 (Clontech). The
resulting vector, gal4-ER-LBD/AF-2, was used as a bait for
screening a human brain cDNA library in yeast strain
CG1945. While sequencing one of the 41 Hisþ/b-galþ clones,
we identiﬁed a single positive 284-bp sequence (clone 22). This
cDNA encodes the predicted 94-amino acid-long protein with
a calculated mass of 10 kDa that is homologous to the human
gene NAG-7 (GenBank Accession No.: AF086709) (Fig. 1A).
The biological functions of the NAG-7 gene are unknown to
date; however, its expression is downregulated in 26% (5/19
cases) of human nasopharyngeal carcinoma cases [39]. In vitro
translation produced a protein of approximately 10 kDa,
consistent with the expected size (Fig. 1B). After plasmid iso-
lation, we re-transformed CG1945 with clone 22 alone, with
the original bait (gal4-ER-LBD/AF-2), or with one of several
control plasmids. We observed positive b-galactosidase
expression only with the combination of clone 22 and gal4-
ER-LBD/AF-2 (Table 3). The protein was designated ERR-10
to signify its function as a co-repressor of ER-a transcriptional
signaling, as well as its size in kilodaltons. The human tissue
speciﬁcity and the mRNA transcript size of ERR-10 wereevaluated through Northern blot analysis (Fig. 1C). Northern
hybridization of the ERR-10 cDNA to mRNA from eight
diﬀerent organs showed a 284-bp band in thymus, prostate,
testes, colon, and ovary, with minimal expression in spleen,
small intestine, and peripheral blood leukocytes.
3.2. In vitro interaction of ERR-10 with ER-a
The interaction between ERR-10 and ER-a was conﬁrmed
by a GST pull-down assay. GST fusion proteins containing the
full-length ER-a were constructed, expressed in E. coli, and
puriﬁed on glutathione–agarose beads as described previously
[35–37]. As shown in Fig. 2B, the GST-wt-ER-a fusion pro-
teins captured IVT [35S]methionine-labeled wt-ERR-10. GST
alone did not capture radiolabeled wt-ERR-10. The presence
of a ligand resulted in a slight increase in ERR-10–ER-a
binding. We also performed the reciprocal experiment with
aﬃnity-puriﬁed GST-ERR-10. GST-ERR-10 bound to gluta-
thione–agarose beads incubated with radiolabeled ER-a. GST-
ERR-10 captured radiolabeled ER-a (Fig. 2C). These results
indicate that the new binding protein ERR-10 interacts directly
with ER-a.
To identify the ER-a binding domain, we also generated two
deletion mutant constructs of ERR-10. The ﬁrst deletion mu-
tant, ERR-10-delN (amino acid 46–94), lacks the N-terminus
and the second deletion mutant, ERR-10-delC (amino acid 1–
46), lacks the C-terminus (Fig. 2A). ERR-10-delC exhibited
appreciable binding to GST-wt-ER-a in both the presence and
absence of E2, whereas ERR-10-delN failed to bind to GST-
wt-ER-a under either circumstance (Fig. 2B). Clearly, the N-
terminus of ERR-10 is required for ERR-10–ER-a interaction.
Analysis of the ERR-10 amino acid sequences revealed that
the N-terminus contains two signature LXXLL sequences
(LPHLL, residues 25–29, termed ERR-10-Box1 and LIWLL,
residues 39–43, termed ERR-10-Box2) resembling the NR-
boxes (Fig. 2A). Furthermore, the two LXXLL motifs local
within the ERR-10-delC bound to the ER-a (Fig. 2B). The
presence of LXXLL motifs, which are required for the inter-
action of several diﬀerent co-regulators with ER (Table 1),
motivated us to assess whether the interaction of ERR-10 and
ER-a was in fact mediated by these LXXLL motifs. To
accomplish this, we generated three ERR-10 constructs
expressing LXXLL mutations: two single mutants (ERR-10-
Box1mut and ERR-10-Box2mut) and one double LXXLL
mutant (ERR-10-Box1/2mut), in which the leucines in the
critical +4 and +5 positions of LXXLL motifs were replaced
with alanines (Fig. 2A). As illustrated in Fig. 2D, both ERR-
10-Box1mut and ERR-10-Box2mut retained the ability to in-
teract with ER-a, albeit in a signiﬁcantly less eﬃcient manner
relative to wt-ERR-10. The ERR-10 with double mutations in
both LXXLL motifs, i.e., ERR-10-Box1/2mut, failed to exhibit
any interaction with ER-a. These results suggest that both
LXXLL motifs of ERR-10 must be intact for optimal inter-
action with ER-a.
To determine the binding domain within the ER-a protein,
we performed GST pull-down assays with various GST-ER-a
mutants, all of which have been described in previous studies
[35–37] (Fig. 3A). As shown in Fig. 3B, IVT-wt-ERR-10
bound to GST-wt-ER-a, GST-ER 2085-595, and GST-ER
373-595, but failed to bind either GST-ER 1-253 or GST-ER
1-353. These results indicate that ERR-10 interacts with ER-a
via binding to the E/F domain of ER-a, which contains the
LBD.
Fig. 1. Nucleotide sequence and amino acid sequence of ERR-10 and ERR-10 expression in various human tissues. (A) cDNA and amino acid
sequences of human ERR-10. The sequence of ERR-10 was conﬁrmed by dideoxy method from positive clones isolated through a yeast two-hybrid
system. cDNA sequences are numbered on the left. As shown, alignment of NR boxes found in ERR-10 is underlined. (B) In vitro translation of
ERR-10 cDNA. The full-length human ERR-10 cDNA was cloned, transcribed, and translated in vitro using rabbit reticulocyte lysate with
[35S]methionine. Radiolabeled protein was fractionated on a 20% SDS–polyacrylamide electrophoresis gel and visualized using autoradiography. The
cDNA encoded a 0.9-kb mRNA in all samples tested (top). A b-actin mRNA probe was used to control for mRNA integrity (bottom). Equal
loading was also assessed via ethidium bromide staining (not shown). (C) Expression of ERR-10 mRNA in various human tissues. Multiple human
tissues (Northern blot II, Clontech) were hybridized with 32P-labeled DNA probes prepared from the original 284 bp ERR-10 cDNA. The same ﬁlter
was stripped and hybridized with GAPDH probe to control for mRNA integrity.
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cells
To determine whether ERR-10 could physically associate
with ER-a in cells, immunoprecipitations were ﬁrst performed
in human 293T cells that had been transiently transfected with
the full-length ERR-10 in a Flag-tagged vector (pCMV-
Tag2B-wt-ERR-10) and the wt-ER-a in a pCMV vector. Totalcell extracts were incubated with the anti-Flag antibody for the
ERR-10 IP and the ER-a protein was co-immunoprecipitated
with ERR-10-Flag (Fig. 4A, lane 3). Similarly, ERR-10 was
identiﬁed by immunoblot analysis using ERR-10 antisera and
determined to be a 10-kDa species present in the ER-a im-
munoprecipitates when total cell extracts from transfected
293T cells were incubated with the anti-ER-a antibody
Table 3
Yeast two-hybrid interaction of ERR-10 with ER-a
Gal-LBD/AF2
GAD-ERR-10 ER-a
)E2 +E2
GAD ) )
GAD-ERR-10 + +
GAD-ERR-10-Box1 + +
GAD-ERR-10-Box2 + +
GAD-ERR-10-Box1/2 ) )
ERR-10 and ER-a interaction was measured as growth on plates
without histidine in the presence (+E2) and absence ()E2) of estrogen
four days after plating. + represents growth; ) represents no growth.
Q. Meng et al. / FEBS Letters 576 (2004) 190–200 195(Fig. 4B, lane 3). Thus, the co-precipitation of ERR-10 with
ER-a occurred when both proteins were overexpressed in 293T
cell lysates. The most important indication of the physiological
signiﬁcance of the ERR-10–ER-a interaction was the visible
formation of an endogenous complex between ERR-10 and
ER-a. Subconﬂuent ER-positive MCF-7 breast cancer cells
were cultured in phenol red-free medium containing dextran-
coated, charcoal-treated FCS 10 nM E2 for 4 h, and then
subjected to immunoprecipitation with an amino-terminal A/B
region-speciﬁc antibody against the ER-a, H226, followed by
IB with ERR-10 antisera. ERR-10 appeared in the ER-a im-
munoprecipitates (Fig. 4C, lane 3); this association only be-
came more apparent after the cells were treated with E2Fig. 2. Interaction of ERR-10 and ER-a. (A) Schematic structure of ERR-10, t
in vitro GST pull-down assays and the location of putative NR boxes.Open bo
with leucine +4 and +5 substitutions with alanine. (B) Full-length wt-ERR-10
10 with an N-terminus deletion (ERR-10-DelN) in a mammalian pCMV-Tag
GST-wt-ER-a fusion proteins immunobilized on GST beads without hormone
capture reagent with a radiolabeled IVT-wt-ER-a. (D) 35S-labeled wt-ERR-10
each reacted to GST-ER-a in the presence of 10 nM E2. A control assay was
ERR-10 or IVT-wt-ER-a to the GST alone. No binding was observed when(Fig. 4C, lane 4). However, we observed that H222, a mono-
clonal antibody directed against the carboxyl-terminal-speciﬁc
antibody of ER-a, was unable to co-precipitate ERR-10
(Fig. 4C, lane 5), even in the presence of E2 (Fig. 4C, lane 6). In
fact, the H222 antibody may have blocked the interaction
between ERR-10 and ER-a, since immunoprecipitation with a
combination of H222 and H226 resulted in a reduction of co-
precipitating ERR-10 (Fig. 5C, lanes 7 and 8), supporting the
theory that an anti-ER-a monoclonal antibody directed
against the LBD/AF-2 region of ER-a can block the interac-
tion between ERR-10 and ER-a.3.4. ERR-10 represses ER-a transcriptional activation in a
ligand-dependent manner
The interaction between ERR-10 and ER-a prompted us to
investigate whether ERR-10 is capable of modulating the ef-
fects of ER-a transcriptional activation on the activity of es-
trogen-responsive promoters. This was accomplished using
transient transfection assays. Two ER-positive breast cancer
cell lines, MCF-7 and T-47D, were transiently transfected with
an equal amount of pCMV-Tag2B-ERR-10 and ERE-TK-
LUC reporter expression vectors in the presence and absence
of E2 (10 nM, 24 h). The luciferase activity was then measured.
The left panel of Fig. 5A shows increased expression levels of
the ERR-10 protein in the cells transfected with the pCMV-
Tag2B-ERR-10 expression vector. Enforced expression of
ERR-10 did not aﬀect basal ER-a expression levels (data nothe ERR-10 deletionmutants, and the LXXLL point mutants used in the
xes indicate consensus LXXLLmotifs and black boxes indicate variants
(1–94), ERR-10 with a C-terminus deletion (ERR-10-DelC), and ERR-
2B expression vector were each translated in vitro and incubated with
()) or with 10 nM E2 (+) as indicated. (C) GST-ERR-10 was used as a
, ERR-10-Box1mut, ERR-10-Box2mut, and ERR-10-Box1/2mut were
performed simultaneously to evaluate the non-speciﬁc binding of IVT-
using GST alone. Input represents 10% of the IVT protein.
Fig. 3. The C-terminus of ER-a is required for ERR-10 binding.
(A) Schematic diagram of ER-a and the ER-a deletion mutations used
in the in vitro GST pull-down assays. The A/B domain at the N-
terminus contains the AF-1 site where other transcription factors
interact. The C/D domain contains the two-zinc ﬁnger structure that
binds to DNA and the E/F domain contains the ligand-binding pocket,
as well as the AF-2 domain. (B) The wt-ER-a and the ER-a mutants
indicated were each fused to GST, immobilized on GST beads, and
reacted with IVT-ERR-10 in the presence of 10 nM E2. No binding
was observed when using GST alone. Input represents 10% of the
amount of labeled IVT-ERR-10 protein.
Fig. 4. In vivo association of ERR-10 with ER-a. Human 293T cells
were transiently transfected with pCMV-Tag2B-ERR-10 and pCMV-
wt-ER-a vectors. The ERR-10 transigene protein was immunopre-
cipitated with an anti-ﬂag-antibody M2 (A); the ER-a transigene
protein was immunoprecipitated with an anti-ER-a N-terminus anti-
body H226 (B). (C) The endogenous ER-a protein from MCF-7 cells
was cultured for 4 h and immunoprecipitated with an anti-ER-a N-
terminus antibody H226, an anti-ER-a C-terminus antibody H222 or
an antibody mix of H222 and H226. The immunoprecipitates were
resolved by 4–20% SDS–PAGE, electroblotted to PVDF membrane,
and visualized by WB analysis, using anti-ER-a antibody H-184 or
anti-ERR-10 sera. This was followed by visualization with an ECL
detection kit, as described in previous studies [35–37].
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was signiﬁcantly activated by 24 h treatment with 10 nM E2
(an about 100-fold increase, set at 100%) compared to when in
the absence of E2 (Fig. 5A, right panel). However, E2 did not
cause any stimulation of ERE-deﬁcient TK-LUC activity. Co-
transfection of ERR-10 signiﬁcantly reduced E2-stimulated
ER-a transcriptional activity (P < 0:01), but ERR-10 did not
aﬀect the basal transcriptional activity of ER-a in the absence
of E2. These results suggest that the eﬀect of ERR-10 on ER-a
signaling is ligand-dependent. The transfection with the
‘‘empty’’ pCMV-Tag2B control vector has little or no eﬀect on
ERE-TK-LUC reporter activation. Furthermore, the extent to
which ER-a transcriptional activation is repressed by ERR-10
is dependent upon the amount of ERR-10 transfected, i.e., in a
dose-dependent manner (Fig. 5B). For example, 0.07, 0.4, and
1.0 lg of ERR-10 vector exhibited about 50% (P < 0:05), 80%
(P < 0:01), and 85% (P < 0:01) reductions in E2-induced
transcriptional activity in both MCF-7 and T-47D cell lines.
When two ER-negative human breast cancer cell lines,
MDA-MB-231 and MDA-MB-468, were co-transfected with
an ER-a expression vector, an ERE2-TK-LUC promoter
vector, and a pCMV-Tag2B-ERR-10 expression vector, simi-
lar results to ERR-10-induced ER-a signaling inhibition wereobserved (Fig. 5C, right panel). Again, co-transfection of the
‘‘empty’’ pCMV-Tag2B control plasmid did not aﬀect ER-a
activity. The ER-a and ERR-10 expressions in the MDA-MB-
231 cell linewere determined byWBanalysis, as illustrated in the
left panel of Fig. 5C. Similar inhibitory, ERR-10-induced eﬀects
on ER-a transcriptional activity were observed in other cell
lines, including human cervical cancer Caski and HeLa cells,
human prostate cancer Du-145 cells, and mouse NIH3T3 cells,
as shown in Fig. 5D. The suppression of ER-a transcription by
ERR-10 does not seem to be a merely general eﬀect upon
transcription, as transcription mediated by the early promoter
SV40 was not inﬂuenced by the expression of ERR-10, as
demonstrated in MCF-7 and MDA-MB-231 cells (data not
shown). These results clearly indicate that ERR-10 is a speciﬁc
repressor for inhibiting ER-a transcriptional activity.
We also determined the eﬀects of ERR-10 on estrogen ac-
tivation of naturally occurring estrogen-responsive promoters
driven by ER-a by using diﬀerent EREs, including the Xenopus
laevis B1 ERE2, the human pS2 ERE, and the human oxytocin
ERE. As shown in Fig. 5E by CAT assays, the activation of
these ER-a-driven ERE promoters by E2 was suppressed by
ERR-10 to diﬀerent extents. These data further suggest that
ERE-10 is a potent modulator in the ER-a signaling trans-
duction pathway.
3.5. The N-terminus and LXXLL motifs of ERR-10 are
required for inhibiting ER-a-mediated transcription
To determine which portion(s) of the ERR-10 protein are
responsible for inhibiting ER-a signaling activation, MCF-7
Fig. 5. Inhibition of ligand activation of ER-a transcriptional activity by ERR-10. (A) ERR-10 inhibits ER-a-mediated ERE promoter activity in a
ligand-dependent fashion. MCF-7 and T-47D cells were cultured in 24-well tissue culture dishes and co-transfected with equal amounts (0.25 lg/well)
of the indicated vectors overnight, incubated in medium 10 nM E2 for 24 h and then harvested for assay of luciferase activity (right panel). The
ERR-10 transigene was monitored by WB in parallel to the luciferase assay (left panel). (B) ERR-10 decreases ER-a-mediated ERE promoter activity
in a dose-dependent manner. Increasing increments (0–10 lg each well/24 well dishes) of ERR-10 plasmid were co-transfected with a 0.25 lg/well of
ERE-TK-LUC vector into MCF-7 and T-47D cells as indicated based on the same protocol in (A). (C,D) ERR-10 inhibition of ER-a signaling in
other cell lines. Breast cancer MDA-MB-231 and MDA-MB-468 cells, human cervical cancer HeLa and Caski cells, human prostate cancer Du-145
cells and murine ﬁbroblastic NIH-3T3 cells were co-transfected overnight with equal amounts (0.25 lg) of pCMV-ER-a, ERE2-TK-LUC and
pCMV-Tag2B-ERR-10 or ‘‘empty’’ pCMV-Tag2B (as a negative control), incubated in mediumE2 (10 nM) for 24 h and then harvested for assay
of luciferase activity. Expressions of the ERR-10 and ER-a transigenes in transfected MDA-MB-231 cells were determined by WB (left panel, C).
Luciferase activity in the presence of E2 is set arbitrarily to 100%. Luciferase values are means standard errors (S.E.s) from three or four inde-
pendent experiments. (E) DU-145 cells were co-transfected with an ER expression vector, a pCMV-Tag2B-ERR-10 expression plasmid, and a CAT
reporter plasmid containing a TATA sequence alone ()) or in combination with a B1, pS2, or OT ERE. Cells were then treated with 10 nM E2 for
24 hr after transfection. CAT activity values are means S.E.s from three separate experiments. The statistical signiﬁcances were analyzed by two-tail
Student’s t test. *P < 0:05; **P < 0:01.
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vector and either a wt-ERR-10, ERR-10-delC, or ERR-10-
delN vector. As shown in Fig. 6B, E2 activation of ER-a-
driven transcriptional activity was signiﬁcantly diminished by
the presence of wt-ERR-10. The C-terminal deletion mutant
ERR-10-delC inhibited ER-a-mediated transcription in a
manner similar to wt-ERR-10. However, the N-terminal de-letion mutant ERR-10-delN failed to have any eﬀect upon ER-
a-mediated transcriptional activation. Neither wt-ERR-10 nor
the two deletion mutants aﬀected the basal level of ERE-LUC
promoter activity in the absence of ligand (Fig. 5A and C).
Thus, consistent with the binding data above (Fig. 2A and D),
the N-terminal region of ERR-10 is also crucial for the ERR-
10-induced inhibition of ER-a transcriptional activation.
Fig. 6. LXXLL motifs were required for ERR-10 to inhibit ER-a
signaling. MCF-7 cells cultured in 24-well tissue culture dishes were
transiently transfected overnight with equal amounts (25 lg/well), in-
dicated vectors by lipofectAMINE 2000. The transfected cells were
harvested for WB to monitor ERR-10 expression (A), and either left
untreated or treated with E2 (10 nM) and subjected to luciferase ac-
tivity assays after 24 h (B). Luciferase activity in the presence of E2 is
set arbitrarily to 100%. The data represent the average of at least four
independent experiments with standard deviations shown as error
bars. The statistical signiﬁcances were analyzed by two-tail Student’s t
test. *P < 0:05; **P < 0:01.
Fig. 7. AF-2 dependent repression of ER-mediated transcription by
ERR-10. Cells were transfected overnight with indicated vectors using
lipofectAMINE 2000, either left untreated or treated with E2 (10 nM),
harvested after 24 h, and subject to luciferase activity assays. Lucif-
erase activity in the presence of E2 is set arbitrarily to 100%. The data
represent the average of at least four independent experiments with
standard deviations shown as error bars. The statistical signiﬁcances
were analyzed by two-tail Student’s t test. *P < 0:05; **P < 0:01.
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ER-a signaling less eﬀectively than did the wt-ERR-10.
However, ERR-10-Box1/2mut completely lost the ability to
attenuate ER-a signaling activation. The proteins of these
LXXLL mutant species by transient transfection were pro-
duced at levels comparable to wt-ERR-10, as determined by
WB analysis (Fig. 6A). These results indicate that the decrease
in ER-a mediated transcription by ERR-10 requires a direct
interaction between ERR-10 and ER-a.
3.6. ERR-10 repression of ER-mediated transcription in an
AF-2-dependent manner
The data shown in Figs. 3B and 4C suggest that the
binding region of ER-a for ERR-10 is located at the N-
terminus. In order to exclude the possibility that ERR-10
interferes with ER transactivation by preventing ER/DNA
interaction, we performed gal4-ER-a/gal4-LUC assays,
which entailed activating a luciferase reporter gene with gal4
DNA-binding sites in the presence of E2. In both MCF-7
and MAD-MB-231 cell lines, co-transfection of wt-ERR-10,
but not the ‘‘empty’’ pCMV-Tag2B control vector, signiﬁ-
cantly attenuated the E2-activated gal4-ER/gal4-LUC re-
porter activity (by approximately 85%, Fig. 7), suggestingthat ERR-10 may function, at least in part, by targeting the
AF-2. ERR-10-Box1/2mut containing mutations in both
LXXLL motifs was markedly defective in its ability to
modulate gal4-ER-a transactivation; however, ERR-10-
Box1mut and ERR-10-Box2mut were both able to inhibit
gal4-ER-a transactivation, albeit less eﬀectively than wild-
type ERR-10, showing 40% and 45% reduction rates in
inhibition ability, respectively. In the absence of gal4-ER-a,
neither wt-ERR-10 nor mutant ERR-10 had any eﬀect on
gal4-LUC activity. Thus, increased expression of ERR-10
speciﬁcally reduces the activity of gal4-ER-a, but this eﬀect
is diminished or disrupted by mutations in either of the two
LXXLL motifs.
3.7. ERR-10 inhibition of E2-stimulated expression of
estrogen-responsive genes
To further conﬁrm ERR-10 co-regulator activity and rule
out any potential artifact eﬀect from the luciferase assay, we
performed RT-PCR assays to investigate the eﬀects of ERR-
10 on expression of several estrogen-response genes in ER-
positive MCF-7 cells. The RT-PCR data presented in Fig. 8
indicate that E2 increases the expression of a panel of es-
trogen-response genes, including E2IG4, efp, cathepsin-D,
and cyclin D1 at mRNA levels. However, the E2-stimulated
expression of these genes was blocked or reduced by ERR-
10 to diﬀerent degrees. For example, the E2-increased
expression of E2IG4 mRNA was completely blocked by
ERR-10, reduced to below even basal levels. In contrast,
ERR-10 had little or no eﬀect on the basal mRNA levels of
these genes in the absence of hormone (data not shown).
Consistent with the mRNA results, it was also found that
ERR-10 inhibited accumulation of these estrogen-response
genes at the post-transcript levels, as evidenced by WB
assays (Fig. 8C). In addition, we found that ERR-10
Fig. 8. ERR-10 inhibition of estrogen-mediated expression of estrogen responsive genes. MCF-7 cells were transiently transfected with pCMV-
Tag2B-ERR-10 or ‘‘empty’’ pCMV-Tag2B (as a control) overnight, incubated with E2 (10 nM) for 24 h and then harvested for RT-PCR assays (A)
and for WB assays (C). Data shown are from a representative experiment that was repeated three times. The densitometric quantitation of mRNA
relative to b-actin and protein relative to a-actin is shown (B,D).
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promoter compared to the control ‘‘empty’’ vector, as shown
by luciferase assays (Fig. 9). Taken together, these resultsFig. 9. ERR-10 inhibition of estrogen-dependent cyclin D1 promoter.
Du-145 cell were transiently transfected with indicated vectors and
post-incubated with and without 10 nM E2 for 24 h. The cells were
ﬁnally harvested for luciferase activity as described in Section 2. The
data represent the average of three independent experiments with
standard deviations shown as error bars. The statistical signiﬁcances
were analyzed by two-tail Student’s t test. *P < 0:01.clearly indicate that ERR-10 is a potent co-regulator for E2-
dependent activation of ER-a transcriptional signaling.
In conclusion, we have presented compelling data re-
garding several properties of a new ER-a-interacting protein,
ERR-10, which we discovered through yeast two-hybrid
assay. The interaction between ERR-10 and ER-a was
conﬁrmed via a GST pull-down assay using both ERR-10
and ER-a capture reagents and by co-immunoprecipitation
of the endogenous proteins. Furthermore, two discrete re-
gions of the two proteins are responsible for the interaction:
the N-terminus of ERR-10 and the C-terminus region con-
taining the LBD of ER-a. The interaction between ERR-10
and ER-a may be direct, since two LXXLL motifs (which
are usually present in NR co-activators) in the N-terminus
of ERR-10 were required for an interaction between the
ERR-10 and ER-a.
Forced expression of ERR-10 signiﬁcantly decreased en-
dogenous and exogenous ER-a-driven ERE luciferase activity
in a ligand- and dose-dependent fashion. In addition, ERR-10
attenuated luciferase activity when the gal4-ER-a was used as
transcriptional activator on a luciferase reporter containing
gal4 DNA-binding sites. However, ERR-10 mutants contain-
ing mutations in both LXXLL motifs exhibited a partial or
complete loss in ER-a transcriptional activity inhibition. These
data indicate that ERR-10 can function as a transcriptional
co-repressor for ER-a. Because ERR-10 is an LXXLL
200 Q. Meng et al. / FEBS Letters 576 (2004) 190–200motif-containing protein, whether the ERR-10 functions as a
general co-regulator in NR transcriptional activity is currently
being investigated in our laboratory. Whether the ERR-10–ER
interaction plays a role in estrogen-related diseases such as
breast cancer needs to be explored in further detail.References
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